Journal of Diabetes (Feb 2023)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics

  • Ildiko Lingvay,
  • Vanita R. Aroda,
  • Julie Broe Honoré,
  • Anne S. Ersbøll,
  • Lise Lotte Nystrup Husemoen,
  • Anders Boeck Jensen,
  • Kasper Sommer Matthiessen,
  • Mikhail Naum Kosiborod

DOI
https://doi.org/10.1111/1753-0407.13363
Journal volume & issue
Vol. 15, no. 2
pp. 190 – 195

Abstract

Read online

Highlights This study demonstrates that initiation of glucagon‐like peptide‐1 receptor agonists among individuals with type 2 diabetes (T2D), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), has remained low in the United States between 2014 and 2019, despite clinical evidence supporting their use for cardiovascular risk reduction. These findings add to the existing literature to highlight a gap in adherence to current practice guidelines, which suggests that most patients with T2D and ASCVD in the United States may not be receiving optimal risk‐reducing therapies.

Keywords